Fresh analysis indicates that individuals who stop using popular weight-loss injections like Mounjaro or Wegovy may regain shed pounds at a significantly accelerated pace than those who stop conventional lifestyle plans.
Research printed in a prominent health publication points out that while overweight people often shed a large proportion of their total mass while using the jabs, the weight returns at an average rate of nearly a kilo each month after stopping.
"Individuals using such drugs must be informed of the risk of fast weight regain when the medication is stopped," stated researcher Dr. Susan Jebb.
That rate of regain implies a return to original weight within about one and a half years.
Analyzing Therapies
The research, which examined dozens of studies involving over 9,000 of patients, contrasted the outcomes of these new drugs with older methods.
The team note that individuals who lose weight through diet and exercise generally see a slower weight regain—approximately 0.1 kg a month—after stopping.
Understanding the Quick Rebound
Experts propose the mechanism of the jabs explains the amplified rebound.
The injections imitate a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Artificially providing the hormone concentrations far above than normal might result in the system to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' means appetite is unsuppressed, making binge eating much more probable."
An Ongoing Disease?
The NHS recommend the injections for individuals with weight-linked health risks, alongside recommended lifestyle changes.
Professionals contend that, given the likelihood of weight regain, the treatment is often long-term.
This perspective is reinforced by pharmaceutical companies, who state that the findings "underscore the long-term character of excess weight," similar to managing diseases like hypertension.
User Experiences
Individuals who have discontinued the jabs describe a intense resurgence of cravings.
"I experienced a switch that goes on and you're instantly starving," described an individual.
This difficulty is exacerbated if users have not developed permanent lifestyle or habit modifications during therapy.
Significant Adoption
Figures indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.
- Adoption is more common among women compared to males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
Finally, researchers caution that while GLP-1 drugs are potent tools for weight loss, they are not a magic solution and maintained weight loss hinges on integrated lifestyle changes.
